Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ELCC-2022-1000x250

Watch the webcasts from our industry partners Satellite Symposia

TTFields: A potential innovative treatment modality in lung cancer 

Novocure

Watch the webcasts

  • Welcome & objectives
    F. Barlesi (Villejuif, France) L. Petruzelka (Prague, Czech Republic
  • What are TTFields - Mechanism of action and experiences in solid tumors
    M. Proescholdt (Regensburg, Germany)
  • TTFields in malignant pleural mesothelioma (MPM) - The STELLAR trial
    G. Ceresoli (Bergamo, Italy)
  • TTFields: A potential innovative treatment modality in lung cancer - The LUNAR trial and beyond
    M. Cobo Dols (Malaga, Spain)
  • Live Q&A / discussion
    L. Petruželka (Prague, Czech Republic) F. Barlesi (Villejuif, France) A. Speakers (Prague, Czech Republic)

Evolving treatment options and practices in EGFR-mutant NSCLC

Janssen Pharmaceutica

Watch the webcasts

  • Welcome and introductions
    A. Passaro (Milan, Italy) E. Felip (Barcelona, Spain)
  • Unmet needs in the management of EGFR+ NSCLC
    N. Leighl (Toronto, Canada) B. Besse (Villejuif, France)
  • Discussion - Unmet needs in the management of EGFR+ NSCLC
    B. Besse (Villejuif, France) N. Leighl (Toronto, Canada)
  • Advances in the treatment of patients with EGFR exon20ins+ NSCLC
    T. Mok (Sha Tin, Hong Kong PRC) A. Minchom (London, United Kingdom)
  • Discussion - Advances in the treatment of patients with EGFR exon20ins+ NSCLC
    A. Minchom (London, United Kingdom) T. Mok (Sha Tin, Hong Kong PRC)
  • Live Q&A
    E. Felip (Barcelona, Spain) A. Passaro (Milan, Italy)
  • Key learnings and closing remarks
    A. Passaro (Milan, Italy) E. Felip (Barcelona, Spain)

Enabling future improvements in cancer care with fast next -generation sequencing (NGS) results

Thermo Fisher Scientific

Watch the webcasts

  • Introduction
    N. Normanno (Napoli, Italy)
  • Complex biomarker driven therapy landscape in NSCLC and latest guidelines
    F. Cappuzzo (Rome, Italy)
  • Molecular pathology - Meeting the challenges of a rapidly evolving biomarker landscape
    J. Beasley (Birmingham, United Kingdom)
  • Removing barriers to routine NGS testing
    P. Hofman (Nice, France)
  • Case studies and panel discussion - Leveraging fast NGS to potentially improve patient outcomes
    Y. Wallis (Birmingham, United Kingdom) P. Hofman (Nice, France) N. Normanno (Napoli, Italy) F. Cappuzzo (Rome, Italy)
  • Audience Q&A
    N. Normanno (Napoli, Italy)

Breaking barriers in thoracic cancers: The expanding possibilities for patients with I-O treatment

Bristol Myers Squibb

Watch the webcasts

  • Welcome & introductions
    A. Scherpereel (Lille, France)
  • Is I-O treatment redefining survival for thoracic cancers?
    A. Scherpereel (Lille, France)
  • The shifting treatment paradigm with I-O in resectable NSCLC
    P. Forde (Baltimore, United States of America)
  • Understanding the potential for long-term survival with I-O in metastatic NSCLC
    N. Reinmuth (Gauting, Germany)
  • Closing remarks & live Q&A
    A. Scherpereel (Lille, France)
  • I-O as a new standard for patients with unresectable MPM
    A. Scherpereel (Lille, France)
  • Closing remarks & live Q&A
    A. Scherpereel (Lille, France) P. Forde (Baltimore, United States of America) N. Reinmuth (Gauting, Germany)

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.